Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 12/2023

Open Access 11-12-2023 | Pancreatic Cancer

Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer – An Overview

Authors: Aleksandra Tarasiuk, PhD, Grzegorz Mirocha, Medical Student, Jakub Fichna, Prof. PhD, DSc

Published in: Current Treatment Options in Oncology | Issue 12/2023

Login to get access

Opinion statement

Pancreatic cancer (PC) remains the deadliest cancer worldwide. Most patients are diagnosed at the advanced or metastatic stage, leading to a poor prognosis. Awareness of the limitations of current therapy and accompanying pain, depression, malnutrition, and side effects of chemoradiotherapy may lead patients and physicians towards complementary and alternative medicine (CAM). CAM refers to a diverse set of medical and healthcare practices, products, and systems that are not part of conventional Western medicine. Despite the low-quality evidence supporting the efficacy of these methods, they remain appealing due to patients' beliefs, fear of death, and the slow development of conventional therapy. Hence, the possibility of using natural products for pancreatic cancer is increasing. CAM options such as: medical cannabis, plants, fungi, herbal formulas, and injections, which originate primarily from traditional Chinese or Japanese medicine i.e. Curcuma longa, Panax ginseng, Poria cocos, Hochuekkito, Juzentaihoto, and Rikkunshito, Shi-quan-da-bu-tang/TJ-48, Huang-qin-tang, Shuangbai San, Wen Jing Zhi Tong Fang, Xiang-Sha-Liu-jun-zi-tang, Aidi injection, Brucea javanica oil emulsion/Yadanziyouru injection, Compound Kushen injection, Huachansu injection, Kangai injection and Kanglaite injections are becoming promising candidates for the management of pancreatic cancer. The abovementioned substances/medications are the most popular or potentially effective in PC treatment and consequently CAM-based adjuvant therapy through improving patients’ quality of life, might be a useful addition in the treatment of pancreatic cancer patients.
Literature
1.
2.
Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. Rev World J Oncol. 2019;10(1):10–27.CrossRef
3.
4.
5.
Meng Q, et al. Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. J Cancer. 2017;8(17):3615–22.PubMedPubMedCentralCrossRef
6.
Fahrmann JF, et al. Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection HHS Public Access. Gastroenterol. 2021;160(4):1373–83.CrossRef
7.
Raptis DA, Fessas C, Belasyse-Smith P, Kurzawinski TR. Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer. Surg. 2010;8(5):239–46.
8.
Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol. 1990;85(4):350–5.PubMed
9.
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–70.PubMedCrossRef
10.
11.
L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman, and L. M. Matrisian, ‘Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states’, Cancer Res., vol. 74, no. 11. American Association for Cancer Research Inc., pp. 2913–2921, 01-Jun-2014.
12.
13.
Kolbeinsson HM, Chandana S, Wright GP, Chung M. ‘Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. J Investig Surg Off J Acad Surg Res. 2023;36(1):2129884.
14.
Conroy T, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395–406.PubMedCrossRef
15.
Neoptolemos JP, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (London, England). 2001;358(9293):1576–85.PubMedCrossRef
16.
•• L. D. Wood, M. I. Canto, E. M. Jaffee, and D. M. Simeone, ‘Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment’, Gastroenterology, Aug. 2022. Review of the current status of surveillance and early detection of PDAC, including populations at high risk and screening approaches as well as outline of the diagnostic approach to PDAC including key treatment considerations, including how therapeutic approaches change with disease stage and targetable subtypes of PDAC
17.
Chawla A, et al. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Ann Surg Oncol. 2020;27(4):1191–200.PubMedCrossRef
18.
19.
Huguet F, Dabout V, Rivin Del Campo E, Gaujoux S, Bachet JB. The role of radiotherapy in locally advanced pancreatic cancer. Br J Radiol. 2021;94(1125):20210044.PubMedPubMedCentralCrossRef
20.
•• F. Pasqualetti et al., ‘Adjuvant radiotherapy in patients with pancreatic adenocarcinoma. Is it still appealing in clinical trials? A meta-analysis and review of the literature’, Anticancer Res., vol. 41, no. 10, pp. 4697–4704, Oct. 2021. The review aimed to assess the impact of postoperative radiotherapy through a meta-analysis of prospective randomized studies.
21.
Chen X, et al. Toll-like receptor 2 and Toll-like receptor 4 exhibit distinct regulation of cancer cell stemness mediated by cell death-induced high-mobility group box 1. EBioMed. 2019;40:135.CrossRef
22.
23.
24.
Laquente B, Calsina-Berna A, Carmona-Bayonas A, Jiménez-Fonseca P, Peiró I, Carrato A. Supportive care in pancreatic ductal adenocarcinoma. Clin Transl Oncol. 2017;19(11):1293–302.PubMedCrossRef
25.
26.
Akizuki N, et al. Prevalence and predictive factors of depression and anxiety in patients with pancreatic cancer: a longitudinal study. Jpn J Clin Oncol. 2016;46(1):71–7.PubMedCrossRef
27.
Janda M, et al. Anxiety, depression and quality of life in people with pancreatic cancer and their carers. Pancreatol. 2017;17(2):321–7.CrossRef
28.
Clark KL, Loscalzo M, Trask PC, Zabora J, Philip EJ. Psychological distress in patients with pancreatic cancer–an understudied group. Psychooncol. 2010;19(12):1313–13.CrossRef
29.
Holland JC, et al. Comparative psychological disturbance in patients with pancreatic and gastric cancer. Am J Psych. 1986;143(8):982–6.CrossRef
30.
Mayr M, Schmid RM. Depression in pancreatic cancer: sense of impending doom. Diges. 2010;82(1 Switzerland):1–3.CrossRef
31.
Boyd AD, et al. Screening for depression, sleep-related disturbances, and anxiety in patients with adenocarcinoma of the pancreas: a preliminary study. Sci World J. 2012;2012:650707.CrossRef
32.
Skelton WP, et al. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Cancer. 2017;49(1):1–8.CrossRef
33.
Cederholm T, et al. Diagnostic criteria for malnutrition – An ESPEN Consensus Statement. Clin Nutr. 2015;34(3):335–40.PubMedCrossRef
34.
Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2012;10(2):90–9.PubMedCrossRef
35.
36.
37.
Hébuterne X, Lemarié E, Michallet M, De Montreuil CB, Schneider SM, Goldwasser F. Prevalence of Malnutrition and Current Use of Nutrition Support in Patients With Cancer. J Parenter Enter Nutr. 2014;38(2):196–204.CrossRef
38.
Bachmann J, Büchler MW, Friess H, Martignoni ME. Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr Cancer. 2013;65(6):827–33.PubMedCrossRef
39.
Ozola Zalite I, et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review. Pancreatol. 2015;15(1):19–24.CrossRef
40.
Olivares O, Vasseur S. Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze. Int J Cancer. 2016;138(4):787–96.PubMedCrossRef
41.
Mayers JR, et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Sci. 2016;353(6304):1161–5.CrossRef
42.
Muñoz Martín AJ, García Alfonso P, Rupérez Blanco AB, Pérez Ramírez S, Blanco Codesido M, Martín Jiménez M. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model. Clin Transl Oncol. 2014;16(10):927–30.PubMedCrossRef
43.
44.
45.
Kunnumakkara AB, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325–48.PubMedCrossRef
46.
Qi F, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015;9(1):16–34.PubMedCrossRef
47.
Schwarz K, Dobiasch S, Nguyen L, Schilling D, Combs SE. ‘Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines. Sci Rep. 2020;10(1):1–10.CrossRef
48.
49.
50.
51.
Sharma RA, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847–54.PubMedCrossRef
52.
Kanai M. Therapeutic applications of curcumin for patients with pancreatic cancer. World J Gastroenterol. 2014;20(28):9384–91.PubMedPubMedCentral
53.
Karaboga Arslan A, Uzunhisarcikli E, Yerer M, Bishayee A. The golden spice curcumin in cancer: A perspective on finalized clinical trials during the last 10 years. J Cancer Res Ther. 2022;18(1):19–26.PubMedCrossRef
54.
Che C-T, Wang ZJ, Chow MSS, Lam CWK. Herb-herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives. Molecules. 2013;18(5):5125–41.PubMedPubMedCentralCrossRef
55.
Wang Z, Xie C, Huang Y, Lam CWK, Chow MSS. Overcoming chemotherapy resistance with herbal medicines: Past, present and future perspectives. Phytochem Rev. 2014;13(1):323–37.CrossRef
56.
Kim S, et al. Anti-cancer effect of panax ginseng and its metabolites: From traditional medicine to modern drug discovery. Processes. 2021;9(8):1–21.CrossRef
57.
Xie J, et al. Separation of ginseng active ingredients and their roles in cancer metastasis supplementary therapy. Curr Drug Metab. 2013;14(5):616–23.PubMedCrossRef
58.
Ni W, et al. Antitumor activities and immunomodulatory effects of ginseng neutral polysaccharides in combination with 5-fluorouracil. J Med Food. 2010;13(2):270–7.PubMedCrossRef
59.
Kim IK, Lee KY, Kang J, Park JS, Jeong J. Immune-modulating Effect of Korean Red Ginseng by Balancing the Ratio of Peripheral T Lymphocytes in Bile Duct or Pancreatic Cancer Patients With Adjuvant Chemotherapy. In Vivo. 2021;35(3):1895–900.PubMedPubMedCentralCrossRef
60.
Barton DL, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230–8.PubMedPubMedCentralCrossRef
61.
Lee TK, Johnke RM, Allison RR, O’Brien KF, Dobbs LJ. Radioprotective potential of ginseng. Mutagenesis. 2005;20(4):237–43.PubMedCrossRef
62.
Zhang L, et al. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Oncogene. 2017;36(9):1297–308.PubMedCrossRef
63.
Newlaczyl AU, Yu LG. Galectin-3 – A jack-of-all-trades in cancer. Cancer Lett. 2011;313(2):123–8.PubMedCrossRef
64.
Yao L-C, et al. Panax notoginseng Saponins Promote Cell Death and Chemosensitivity in Pancreatic Cancer through the Apoptosis and Autophagy Pathways. Anticancer Agents Med Chem. 2021;21(13):1680–8.PubMedCrossRef
65.
Qi F, et al. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2010;4(6):297–307.PubMed
66.
Cheng S, Eliaz I, Lin J, Sliva D. Triterpenes from Poria cocos suppress growth and invasiveness of pancreatic cancer cells through the downregulation of MMP-7. Int J Oncol. 2013;42(6):1869–74.PubMedPubMedCentralCrossRef
67.
Cheng S, Castillo V, Sliva D. CDC20 associated with cancer metastasis and novel mushroom-derived CDC20 inhibitors with antimetastatic activity. Int J Oncol. 2019;54(6):2250–6.PubMed
68.
69.
Marmiroli M, Pietrini F, Maestri E, Zacchini M, Marmiroli N, Massacci A. Growth, physiological and molecular traits in Salicaceae trees investigated for phytoremediation of heavy metals and organics. Tree Physiol. 2011;31(12):1319–34.PubMedCrossRef
70.
McCulloch M, Ly H, Broffman M, See C, Clemons J, Chang R. ‘Chinese Herbal Medicine and Fluorouracil-Based Chemotherapy for Colorectal Cancer: A Quality-Adjusted Meta-Analysis of Randomized Controlled Trials. Integr Cancer Ther. 2016;15(3):285–307.PubMedPubMedCentralCrossRef
71.
Yang X, et al. Survival Benefits of Western and Traditional Chinese Medicine Treatment for Patients With Pancreatic Cancer. Med (Baltimore). 2015;94(26):e1008.CrossRef
72.
73.
74.
75.
Ikemoto T, et al. Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. Int J Clin Oncol. 2014;19(1):81–6.PubMedCrossRef
76.
Wang Z, et al. An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics. BioSci Trends. 2018;12(3):220–39 International Advancement Center for Medicine and Health Research Co., Ltd.PubMedCrossRef
77.
Lee JY, Kim EH, Yoon J-H, Eo W, Yoon SW. Traditional Herbal Medicine, Sipjeondaebo-Tang, for Cancer-Related Fatigue: A Randomized, Placebo-Controlled. Preliminary Study Integr Cancer Ther. 2021;20:15347354211040830.PubMed
78.
79.
Cheon C, et al. Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2017;2017:8780325.PubMedPubMedCentralCrossRef
80.
Ishiura Y, et al. Effect of Japanese Traditional Medicine, TJ-48, on the Quality of Life of Patients with Non-Small Cell Lung Cancer Receiving Outpatient Chemotherapy. Gan To Kagaku Ryoho. 2016;43(3):331–4.PubMed
81.
Liu SH, Cheng YC. Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy. J Ethnopharmacol. 2012;140(3):614–23.PubMedCrossRef
82.
Chu E. Wedding Rigorous Scientific Methodology and Ancient Herbal Wisdom to Benefit Cancer Patients: The Development of PHY906. Oncol (Williston Park). 2018;32(2):e20–7.
83.
• X. Ye, D. Lu, X. Chen, S. Li, Y. Chen, and L. Deng, ‘A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain’, J. Pain Symptom Manage., vol. 51, no. 6, pp. 979–986, Jun. 2016. Randomized, Double-Blind, Placebo-Controlled Trial conducted to evaluate the effect of Shuangbai San on relieving pain and improving QOL in primary liver cancer patients with cancer pain.
84.
Cai P, et al. A Chinese medicine warm compress (Wen Jing Zhi Tong Fang), combined with WHO 3-step analgesic ladder treatment for cancer pain relief: A comparative randomized trial. Med (Baltimore). 2018;97(11):e9965.CrossRef
85.
Kuo YT, et al. Complementary Chinese Herbal Medicine Therapy Improves Survival of Patients With Pancreatic Cancer in Taiwan: A Nationwide Population-Based Cohort Study. Integr Cancer Ther. 2018;17(2):411–22.PubMedCrossRef
86.
Xie G, Cui Z, Peng K, Zhou X, Xia Q, Xu D. Aidi Injection, a Traditional Chinese Medicine Injection, Could Be Used as an Adjuvant Drug to Improve Quality of Life of Cancer Patients Receiving Chemotherapy: A Propensity Score Matching Analysis. Integr Cancer Ther. 2019;18:153473541881079. https://​doi.​org/​10.​1177/​1534735418810799​.CrossRef
87.
•• H. Wang et al., ‘A novel strategy to reveal clinical advantages and molecular mechanism of aidi injection in the treatment of pancreatic cancer based on network meta-analysis and network pharmacology’, J. Ethnopharmacol., vol. 285, Mar. 2022. Meta-anlysis to evaluate the efficacy and clinical benefits of TCMIs in combination with chemotherapy in the treatment of pancreatic cancer and to explore the mechanism of clinical advantage of Aidi injection.
88.
Wei Li K, et al. Brucea javanica: A review on anticancer of its pharmacological properties and clinical researches. Phytomed. 2021;86:153560.CrossRef
89.
Yang H, Tong Z, Shen L, Sun Y, Hoffman RM, Huang J. Brucea javanica Increases Survival and Enhances Gemcitabine Efficacy in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Pancreatic Cancer. Anticancer Res. 2020;40(9):4969–78.PubMedCrossRef
90.
Zhang D, Wu J, Liu S, Zhang X, Zhang B. Network meta-analysis of Chinese herbal injections combined with the chemotherapy for the treatment of pancreatic cancer. Med (Baltimore). 2017;96(21):e7005.CrossRef
91.
• J. Chen, S. Chen, X. Yang, S. Wang, and W. Wu, ‘Efficacy and safety of Brucea javanica oil emulsion injection as adjuvant therapy for cancer: An overview of systematic reviews and meta-analyses’, Phytomedicine, vol. 102, Jul. 2022. The overview to assess the SRs/MAs of BJOEI, which provide a comprehensive evidence map to guide clinicians. Besides, this study provided a promising direction for future research to promote the generation of advanced evidence.
92.
Wang X, et al. Efficacy and Safety of Brucea javanica Oil Emulsion Injection in the Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis. Front Nutr. 2021;8:784164.PubMedPubMedCentralCrossRef
93.
•• P. Su, Y. Leng, J. Liu, Y. Yu, Z. Wang, and H. Dang, ‘Comparative Analysis of the Efficacy and Safety of Different Traditional Chinese Medicine Injections in the Treatment of Cancer-Related Pain: A Bayesian Network Meta-Analysis’, Frontiers in Pharmacology, vol. 12. Frontiers Media S.A., 07-Feb-2022. Network Meta-Analysis which aims to compare the efficacy and safety of different regimens of TCMIs for CRP.
94.
95.
Roychoudhury P, Kapoor AK, Walsh D, Cortes H, Clarke H. State of the science: cannabis and cannabinoids in palliative medicine-the potential. BMJ Support Palliat Care. 2021;11:299–302.PubMedCrossRef
96.
97.
•• B. Xu et al., ‘Gene Differential Expression and Interaction Networks Illustrate the Biomarkers and Molecular Biological Mechanisms of Unsaponifiable Matter in Kanglaite Injection for Pancreatic Ductal Adenocarcinoma’, Biomed Res. Int., vol. 2022, 2022. Original study which used network pharmacology, molecular docking, and database verification methods to investigate the molecular biological mechanisms of unsaponifiable matter.
98.
Schwartzberg LS, et al. A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer. J Cancer. 2017;8(10):1872–83.PubMedPubMedCentralCrossRef
99.
100.
Turgeman I, Bar-Sela G. Cannabis for cancer - illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opin Investig Drugs. 2019;28(3):285–96.PubMedCrossRef
101.
102.
•• A. I. Fraguas-Sánchez, A. Fernández-Carballido, R. Simancas-Herbada, C. Martin-Sabroso, and A. I. Torres-Suárez, ‘CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer’, Int. J. Pharm., vol. 574, p. 118916, Jan. 2020. Original paper which data evidences the promising inclusion of CBD in conventional breast cancer chemotherapy and the use of CBD-Mps for the extended release of this cannabinoid, optimising the effect of the chemotherapeutic agents.
103.
104.
105.
Bar-Sela G, Vorobeichik M, Drawsheh S, Omer A, Goldberg V, Muller E. The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care. Evid Based Complement Alternat Med. 2013;2013:1–8. https://​doi.​org/​10.​1155/​2013/​510392.CrossRef
106.
De Moulin D, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328–35.PubMedPubMedCentralCrossRef
107.
Krcevski-Skvarc N, Wells C, Häuser W. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation. Eur J Pain. 2018;22(3):440–54.PubMedCrossRef
108.
Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167–79.PubMedCrossRef
109.
Noyes R, Brunk SF, Avery DH, Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18(1):84–9.PubMedCrossRef
110.
Van Sickle MD, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterol. 2001;121(4):767–74.CrossRef
111.
L. A. Smith, F. Azariah, V. T. Lavender, N. S. Stoner, and S. Bettiol, ‘Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy’, Cochrane database Syst Rev. 2015, vol. 2015, no. 11
112.
113.
Whiting PF, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–73.PubMedCrossRef
114.
Lane M, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. 1991;6(6):352–9.PubMedCrossRef
115.
Tramèr MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303):16–21.PubMedPubMedCentralCrossRef
116.
Turcott JG, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26(9):3029–38.PubMedCrossRef
117.
Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4(8):1729–43.PubMedCrossRef
118.
Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJA, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17(5):293–306.PubMedCrossRef
119.
Brisbois TD, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol Off J Eur Soc Med Oncol. 2011;22(9):2086–93.CrossRef
120.
Kleine-Brueggeney M, Greif R, Brenneisen R, Urwyler N, Stueber F, Theiler LG. ‘Intravenous Delta-9-Tetrahydrocannabinol to Prevent Postoperative Nausea and Vomiting: A Randomized Controlled Trial. Anesth Analg. 2015;121(5):1157–64.PubMedCrossRef
121.
Niesink RJM, van Laar MW. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front Psych. 2013;4:130.
122.
Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW. Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int. 2015;112(16):271–8.PubMedPubMedCentral
123.
MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9.PubMedCrossRef
124.
•• N. N. Sanford, D. J. Sher, C. Ahn, A. A. Aizer, and B. A. Mahal, ‘Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States’, JAMA Oncol., vol. 5, no. 5, pp. 735–737, May 2019. This cross-sectional study analyzes the proportion of patients with cancer and cancer survivors who use complementary and alternative medicine (CAM) without disclosing this information to their physicians.
Metadata
Title
Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer – An Overview
Authors
Aleksandra Tarasiuk, PhD
Grzegorz Mirocha, Medical Student
Jakub Fichna, Prof. PhD, DSc
Publication date
11-12-2023
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 12/2023
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-023-01146-4

Other articles of this Issue 12/2023

Current Treatment Options in Oncology 12/2023 Go to the issue

ReviewPaper

Perioperative Immunotherapy in Non-Small Cell Lung Cancer

ReviewPaper

Precision medicine in urothelial carcinoma

ReviewPaper

Nonsurgical therapeutic strategies for nonmelanoma skin cancers

ReviewPaper

Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy

ReviewPaper

Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer

ReviewPaper

Circulating biomarkers in neuroendocrine neoplasms
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits